Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can community hospitals in zambia master severe disease care?

NCT ID NCT07753681

Disease control Sponsor: Centre for Infectious Disease Research in Zambia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests a new model of care called PEN-Plus, which brings specialized treatment for severe chronic diseases like diabetes, heart conditions, and sickle cell disease to first-level hospitals in Zambia. The goal is to train local health workers and set up clinics to manage these complex conditions closer to home. The study will see if this approach increases the number of patients diagnosed and treated effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supportive treatment including insulin, hydroxyurea, and clinic/training center setup
What this could lead to
If successful, this could expand access to life-saving care for severe chronic diseases in low-resource settings, potentially improving outcomes for thousands.
What could go wrong
The trial is early and focuses on implementation, so benefits may vary. Challenges like drug supply and training could limit impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,084 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All individuals in Zambian community that live around the Intervention facilities and present with NCDs or are known NCD patients.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presenting with chronic NCDs Exclusion Criteria: * Refusing to be followed up prospectively for routine visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer congenital heart disease diabetes mellitus epilepsy heart disorder heart failure hypertensive disorder impaired renal function disease kidney disorder mental disorder neoplasm rheumatic heart disease sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cardiac diseases Congenital heart disease Diabetes mellitus Epilepsy Heart failure Hypertension Kidney disease Mental health disorders Rheumatic heart disease Sickle cell disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Matero First Level Hospital

    RECRUITING

    Lusaka, Lusaka Province, 10101, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.